keyword
MENU ▼
Read by QxMD icon Read
search

classical hodgkin lymphoma

keyword
https://www.readbyqxmd.com/read/28427406/latent-membrane-protein-1-lmp1-expression-in-hodgkin-lymphoma-and-its-correlation-with-clinical-and-histologic-parameters
#1
Atif Ali Hashmi, Zubaida Fida Hussain, Kashif Ali Hashmi, Muhammad Irfan Zafar, Muhammad Muzzammil Edhi, Naveen Faridi, Mehmood Khan
BACKGROUND: Hodgkin lymphoma is one of the most prevalent lymphoproliferative disorders in Pakistan; however, no risk factors for this disease have yet to be established in our population. Epstein-Barr virus (EBV) is a well-known risk factor for Hodgkin lymphoma in endemic regions of the world; however, frequency of its association in our population has not been widely studied. Latent membrane protein 1 (LMP1) expression by immunohistochemistry (IHC) is a surrogate marker of EBV in Hodgkin lymphoma...
April 20, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28418952/fdg-pet-ct-findings-of-nodular-sclerosis-subtype-classic-hodgkin-lymphoma-presented-as-mediastinal-nodal-lesions-at-onset-but-as-predominant-osseous-disease-at-relapse
#2
Kun Zheng, Hongming Zhuang
Nodular sclerosis-subtype classic Hodgkin lymphoma in general manifests as bulky mediastinal lymphadenopathy but very rarely involves bones. We report FDG PET/CT findings of a 19-year-old man with pathology-proven, nodular sclerosis-type classic Hodgkin lymphoma. His initial FDG PET/CT scan at the diagnosis showed only hypermetabolic lymphadenopathy in the mediastinum. However, the FDG PET/CT acquired when the disease recurred 20 months later showed predominant osseous disease without additional nodal lesions outside the mediastinum...
April 17, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28395108/b-cell-and-classical-hodgkin-lymphomas-associated-with-immunodeficiency-2015-sh-eahp-workshop-report-part-2
#3
Daphne de Jong, Margaretha G M Roemer, John K C Chan, John Goodlad, Dita Gratzinger, Amy Chadburn, Elaine S Jaffe, Jonathan Said, Yasodha Natkunam
Objectives: The 2015 Workshop of the Society for Hematopathology/European Association for Haematopathology submitted small and large B-cell lymphomas (BCLs), including classical Hodgkin lymphoma (CHL), in the context of immunodeficiency. Methods: Clinicopathologic and molecular features were studied to explore unifying concepts in malignant B-cell proliferations across immunodeficiency settings. Results: Cases submitted to the workshop spanned small BCLs presenting as nodal or extranodal marginal zone lymphoma and lymphoplasmacytic lymphoma, Epstein-Barr virus (EBV) positive in 75% of cases...
February 1, 2017: American Journal of Clinical Pathology
https://www.readbyqxmd.com/read/28389060/paraneoplastic-limbic-encephalitis-with-sox1-and-pca2-antibodies-and-relapsing-neurological-symptoms-in-an-adolescent-with-hodgkin-lymphoma
#4
M Kunstreich, J H Kreth, P T Oommen, J Schaper, M Karenfort, O Aktas, D Tibussek, F Distelmaier, A Borkhardt, M Kuhlen
BACKGROUND: Immune cross-reactivity between malignant and normal tissues causes the rare, so called paraneoplastic syndrome (PS). In approximately 60% of the patients, various onconeural antibodies are detectable in the cerebrospinal fluid (CSF) and are associated with typical tumour entities. METHODS: We report an unusual case of paraneoplastic limbic encephalitis (PLE) in a 17-year-old adolescent with classical Hodgkin lymphoma. RESULTS: He presented with a variety of neurologic and neuropsychiatric symptoms, profound B-symptoms and typical MRI findings including hyperintense lesions with contrast enhancement in the medial temporal lobe and limbic system...
March 27, 2017: European Journal of Paediatric Neurology: EJPN
https://www.readbyqxmd.com/read/28387200/synchronous-nodal-involvement-by-metastatic-adenocarcinoma-and-classical-hodgkin-s-lymphoma
#5
Ritesh Sachdev, Shalini Goel, Ruchika K Goel, Smeeta Gajendra, Nitin Sood
No abstract text is available yet for this article.
April 7, 2017: Turkish Journal of Haematology: Official Journal of Turkish Society of Haematology
https://www.readbyqxmd.com/read/28380678/clinicopathological-analysis-of-methotrexate-associated-lymphoproliferative-disorders-comparison-of-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma-types
#6
Yuka Gion, Noriko Iwaki, Katsuyoshi Takata, Mai Takeuchi, Keiichiro Nishida, Yorihisa Orita, Tomoyasu Tachibana, Tadashi Yoshino, Yasuharu Sato
Patients with rheumatoid arthritis often develop methotrexate-associated lymphoproliferative disorders (MTX-LPD) during MTX treatment. MTX-LPD occasionally regresses spontaneously after simply discontinuing MTX treatment. In patients without spontaneous regression, additional chemotherapy is required to avoid disease progression. However, the differences between spontaneous and non-spontaneous regression have yet to be elucidated. To clarify the factors important for spontaneous regression, we analyzed the clinicopathological features of 51 patients with rheumatoid arthritis who developed MTX-LPD (diffuse large B-cell lymphoma [DLBCL]-type [n = 34] and classical Hodgkin lymphoma [CHL]-type [n = 17])...
April 5, 2017: Cancer Science
https://www.readbyqxmd.com/read/28377796/redox-regulating-enzymes-and-connected-microrna-regulators-have-prognostic-value-in-classical-hodgkin-lymphomas
#7
Peeter Karihtala, Katja Porvari, Ylermi Soini, Kirsi-Maria Haapasaari
There are no previous studies assessing the microRNAs that regulate antioxidant enzymes in Hodgkin lymphomas (HLs). We determined the mRNA levels of redox regulating enzymes peroxiredoxins (PRDXs) I-III, manganese superoxide dismutase (MnSOD), nuclear factor erythroid-derived 2-like 2 (Nrf2), and Kelch-like ECH-associated protein 1 (Keap1) from a carefully collected set of 41 classical HL patients before receiving any treatments. The levels of redoxmiRs, miRNAs known to regulate the above-mentioned enzymes, were also assessed, along with CD3, CD20, and CD30 protein expression...
2017: Oxidative Medicine and Cellular Longevity
https://www.readbyqxmd.com/read/28368262/intravenacaval-invasion-of-classical-hodgkin-lymphoma-detected-with-18-f-fluorodeoxyglucose-18-f-fdg-pet-mri
#8
Shinichi Makita, Hiroaki Kurihara, Kensei Tobinai
No abstract text is available yet for this article.
April 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28363910/pembrolizumab-approved-for-hodgkin-lymphoma
#9
(no author information available yet)
The FDA has approved pembrolizumab for adults and children with classical Hodgkin lymphoma whose disease is refractory to or has relapsed after at least three prior therapies. The approval marks the first time that a PD-1 inhibitor has been indicated for blood cancers-and for children.
March 31, 2017: Cancer Discovery
https://www.readbyqxmd.com/read/28358739/hiv-infection-has-no-prognostic-impact-on-advanced-stage-hodgkin-lymphoma-treated-with-doxorubicin-bleomycin-vinblastine-and-dacarbazine
#10
Marc Sorigué, Olga García, Gustavo Tapia, Maria J Baptista, Miriam Moreno, José-Luis Mate, Juan M Sancho, Evarist Feliu, Josep-Maria Ribera, José-Tomás Navarro
OBJECTIVE: Classical Hodgkin lymphoma (cHL) is a non-AIDS-defining cancer with good response to chemotherapy in the combined antiretroviral therapy (cART) era. The aim of the study was to compare the characteristics, the response with treatment and survival of advanced-stage cHL treated with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) between cART-treated HIV-positive and HIV-negative patients. DESIGN AND METHODS: We retrospectively analyzed advanced-stage cHL patients from a single institution, uniformly treated with ABVD...
March 29, 2017: AIDS
https://www.readbyqxmd.com/read/28341757/elevated-serum-levels-of-scd30-and-il-6-and-detectable-il-10-precede-classical-hodgkin-lymphoma-diagnosis
#11
Lynn I Levin, Elizabeth C Breen, Brenda M Birmann, Julie L Batista, Larry I Magpantay, Yuanzhang Li, Richard F Ambinder, Nancy E Mueller, Otoniel Martínez-Maza
BACKGROUND: We investigated whether an immune system environment characterized by elevated serum levels of B-cell activation molecules was associated with the subsequent development of classical Hodgkin lymphoma (cHL). METHODS: We measured serum levels of B cell stimulatory cytokines, interleukin (IL)-6 and IL-10, soluble CD30 (sCD30) and total IgE prior to cHL diagnosis in 103 cases and 206 matched controls with archived specimens in the DoD Department of Defense Serum Repository...
March 24, 2017: Cancer Epidemiology, Biomarkers & Prevention
https://www.readbyqxmd.com/read/28334025/hla-expression-and-hla-type-associations-in-relation-to-ebv-status-in-hispanic-hodgkin-lymphoma-patients
#12
Luke B Fletcher, Rianne N Veenstra, Eric Y Loo, Amie E Hwang, Imran N Siddiqi, Lydia Visser, Bouke G Hepkema, Ilja M Nolte, Anke van den Berg, Wendy Cozen, Arjan Diepstra
A proportion of classical Hodgkin lymphomas harbor the Epstein Barr virus (EBV). We previously demonstrated that associations between Human Leukocyte Antigen (HLA) alleles and susceptibility to EBV+ classical Hodgkin lymphoma differ between European and Chinese populations. Data on Hispanic populations is missing. Here we examined the association between HLA type, tumor cell HLA expression and other characteristics in Hispanic Hodgkin lymphoma patients. Hispanic Hodgkin lymphoma patients diagnosed at the Los Angeles County-University of Southern California Medical Center from 2000-2012 were included (n = 65)...
2017: PloS One
https://www.readbyqxmd.com/read/28327905/phase-ii-study-of-idelalisib-a-selective-inhibitor-of-pi3k%C3%AE-for-relapsed-refractory-classical-hodgkin-lymphoma
#13
A K Gopal, M A Fanale, C H Moskowitz, A R Shustov, S Mitra, W Ye, A Younes, A J Moskowitz
Background: The phosphatidylinositol-3-kinase delta (PI3Kδ) inhibitor idelalisib has been shown to block downstream intracellular signaling, reduce the production of prosurvival chemokines and induce apoptosis in classical Hodgkin lymphoma (HL) cell lines. It has also been shown to inhibit regulatory T cells and myeloid-derived suppressor cells in other tumor models. We hypothesized that inhibiting PI3Kδ would have both direct and indirect antitumor effects by directly targeting the malignant cells as well as modulating the inflammatory microenvironment...
January 24, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28318345/novel-agents-in-classical-hodgkin-lymphoma
#14
Sven Borchmann, Bastian von Tresckow
Classical Hodgkin lymphoma (cHL) is the most common hematological malignancy in young adults and can be cured in most cases. However, relapsed and refractory Hodgkin lymphoma, certain patient groups, such as elderly patients, and toxicity of first-line treatment still pose significant challenges. Consequently, new treatment options are needed. Recently, many new treatment concepts have been evaluated in clinical trials. Targeted drug-antibody conjugates and immune checkpoint inhibitors have decisively changed treatment approaches...
March 20, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28294688/successful-treatment-of-classical-hodgkin-lymphoma-during-pregnancy-in-malawi
#15
Edwards Kasonkanji, Bongani Kaimila, Amy Amuquandoh, Maria Chikasema, Blessings Tewete, Toon van der Gronde, Satish Gopal
No abstract text is available yet for this article.
February 7, 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28268254/plasma-epstein-barr-virus-dna-for-pediatric-burkitt-lymphoma-diagnosis-prognosis-and-response-assessment-in-malawi
#16
Katherine D Westmoreland, Nathan D Montgomery, Christopher C Stanley, Nader Kim El-Mallawany, Peter Wasswa, Toon van der Gronde, Idah Mtete, Mercy Butia, Salama Itimu, Mary Chasela, Mary Mtunda, Coxcilly Kampani, N George Liomba, Tamiwe Tomoka, Bal M Dhungel, Marcia K Sanders, Robert Krysiak, Peter Kazembe, Dirk P Dittmer, Yuri Fedoriw, Satish Gopal
Point-of-care tools are needed in sub-Saharan Africa (SSA) to improve pediatric Burkitt lymphoma (BL) diagnosis and treatment. We evaluated plasma Epstein-Barr virus (pEBV) DNA as a pediatric BL biomarker in Malawi. Prospectively enrolled children with BL were compared to classical Hodgkin lymphoma (cHL) and nonlymphoma diagnoses. Pediatric BL patients received standardized chemotherapy and supportive care. pEBV DNA was measured at baseline, mid-treatment, and treatment completion. Of 121 assessed children, pEBV DNA was detected in 76/88 (86%) with BL, 16/17 (94%) with cHL, and 2/16 (12%) with nonlymphoma, with proportions higher in BL versus nonlymphoma (p < 0...
June 1, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28267244/a-multicenter-phase-ii-study-of-nivolumab-in-japanese-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma
#17
Dai Maruyama, Kiyohiko Hatake, Tomohiro Kinoshita, Noriko Fukuhara, Ilseung Choi, Masafumi Taniwaki, Kiyoshi Ando, Yasuhito Terui, Yusuke Higuchi, Yasushi Onishi, Yasunobu Abe, Tsutomu Kobayashi, Yukari Shirasugi, Kensei Tobinai
Overexpression of programmed death-1 (PD-1) ligands contributes to an immunosuppressive microenvironment. Nivolumab is a PD-1-blocking antibody that inhibits the PD-1 pathway and showed good efficacy in several types of malignancy. This phase II study examined the efficacy and safety of nivolumab in 17 Japanese patients with refractory/relapsed classical Hodgkin lymphoma previously treated with brentuximab vedotin. Sixteen patients were included in efficacy analyses and 17 in safety analyses. The primary endpoint was the centrally assessed objective response rate (ORR)...
March 7, 2017: Cancer Science
https://www.readbyqxmd.com/read/28249824/a-new-construct-of-antibody-drug-conjugates-for-treatment-of-b-cell-non-hodgkin-s-lymphomas
#18
Libin Zhang, Yixin Fang, Jindřich Kopeček, Jiyuan Yang
The aim of this study was to develop a new class of antibody-drug conjugates (ADCs) with the potential to not only enhance treatment efficacy but also improve tolerability for patients with B-cell lymphomas. Classic ADCs consist of monoclonal antibodies (mAbs) linked to drugs or toxins. They selectively deliver toxic moieties to tumor cells. As such, they greatly improve the therapeutic index compared to traditional chemotherapeutic agents. However, the therapeutic efficacy and safety of ADCs are dependent on linker stability and payload toxicity...
February 26, 2017: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/28247950/use-of-brentuximab-vedotin-as-salvage-therapy-pre-allogeneic-stem-cell-transplantation-in-relapsed-refractory-cd30-positive-lympho-proliferative-disorders-a-single-centre-experience
#19
Heshani Mediwake, Kirk Morris, Cameron Curley, Jason Butler, Glen Kennedy
AIM: To assess the outcome of use of brentuximab as a bridge to allogeneic stem cell transplant (SCT) in patient with relapsed / refractory CD30+ classic Hodgkin Lymphoma c(HL) and Anaplastic Large Cell Lymphoma (ALCL). METHODS: Outcomes of consecutive patients with relapsed / refractory cHL / ALCL treated with brentuximab as a bridge to SCT were determined by retrospective review of individual medical records. Survival analysis was measured from start of brentuximab treatment...
March 1, 2017: Internal Medicine Journal
https://www.readbyqxmd.com/read/28242522/targeting-the-programmed-death-1-pathway-in-lymphoid-neoplasms
#20
REVIEW
Chi Young Ok, Ken H Young
Programmed death-1 (PD-1) is a co-inhibitory molecule and is seen in CD4+ and CD8+ T cells. Upon binding to its ligands, programmed death ligand-1 (PD-L1) and -2 (PD-L2), PD-1 negatively regulates interleukin 2 (IL-2) production and T cell proliferation. Activated effector T-cells, which kill cancer cells, can be affected by PD-1 signaling in some lymphoid neoplasm that express PD-L1 or PD-L2. PD-L1 expression in tumor cells can be induced by extrinsic signal (i.e. interferon gamma) or intrinsic signals, such as genetic aberrations involving 9p24...
March 2017: Cancer Treatment Reviews
keyword
keyword
49025
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"